ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 310 participants.

Also called NCT01228227

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 310 participants (planned count) (from the registry)
Sponsor
Gennaro Sardella (from the registry)
Registry
  • NCT NCT01228227
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01228227. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
Acronym
ROMAIIReload
Condition
Assess the Periprocedural Myocardial Necrosis
Intervention (Drug)
ATORVASTATIN 80 mg
Intervention (Drug)
ROSUVASTATIN 40 mg
Lead sponsor
Gennaro Sardella (class: other)

Record details

Record id
cardio:ct-nct01228227
Content hash
3a10ba5a3baa85f9e0002a7b54f26ed29777dac6ff264af12f5f91e5e7e3e596